Male subfertility/infertility is acknowledged to contribute significantly to infertility problems experienced by couples. In some instances, morphological and/or physiological defects known to interfere with normal sperm function can be identified. However, in others, no obvious cause of fertilization failure can be identified. The recent introduction of molecular methods has made it possible to diagnose more subtle defects that could affect the function of spermatozoa produced by some males. For others, though, the problems may result from defects in the physiological mechanisms that need to be activated in spermatozoa so that they 'switch on' functionally following their release from the male reproductive tract. Capacitation, the term applied to this 'switching on', encompasses a number of changes that, collectively, confer fertilizing potential on sperm cells. This article focuses on two extrinsic factors, one a protein and one a very small peptide, that become associated with spermatozoa either in the epididymis or following contact with seminal plasma. These factors modulate capacitation in vitro in ways that could be very relevant to fertilization in vivo, possibly helping to maximize the fertilizing potential of the few cells that reach the site of fertilization. In some men, defects in either of the factors and the systems they modulate could result in defective fertilization. However, by understanding the underlying mechanisms, it may prove possible to develop new diagnostic techniques and new therapeutic treatments to alleviate the infertility.
Introduction
For some time it has been clear that male subfertility/infertility may contribute substantially to the overall incidence of infertility in the general population (e.g. Hull et ai, 1985; ESHRE Capri Workshop, 1996; Jeremias and Witkin, 1996; Aitken, 1997) . In some instances, evaluation of semen has revealed qualitative defects, e.g. specific morphological abnormalities (misshapen sperm heads, etc.) or physiological abnormalities (defective motility) and/or quantitative defects, e.g. very few or no cells present in the ejaculate, that could account for faulty fertilization. The underlying causes of production of defective spermatozoa are usually unknown, although in recent years evidence has emerged that in some men genetic abnormalities can cause serious disruption of sperm production. At least some of these aspects will be addressed in other articles in this supplement.
In other instances, men may produce reasonable numbers of spermatozoa that appear morphologically normal but prove to be non-fertilizing, even when tested in vitro. How do we identify the underlying problem in such individuals? Jeremias and Witkin (1996) recently reviewed new information obtained by applying molecular methods to the diagnosis of male infertility. For example, the use of the polymerase chain reaction has allowed identification of various, often asymptomatic, male genital tract infections that might be a cause of defective sperm function. In some instances, the cellular defects may result from immunological consequences of the infection, e.g. the presence of elevated numbers of leukocytes that can release high concentrations of reactive oxygen species which are known to have deleterious effects on sperm function (e.g. Aitken, 1997; de Lamirande et al, 1997) , or the production of antibodies directed against various sperm-associated molecules. In other instances, defects involving genes on the Y chromosome (e.g. Qureshi et al, 1996) or those present in mitochondrial DNA (Cummins et al, 1994) may be the cause.
However, there is yet another category, in which there may be defects relating to extrinsic factors that are normally associated with spermatozoa and that play fundamental roles in the events that turn non-fertilizing cells into potentially fertilizing ones. Experimental evidence obtained in numerous studies on a range of species indicates that there are both inhibitory and stimulatory molecules that may act simultaneously on spermatozoa and that can modulate the acquisition of fertilizing ability. Thus, it is reasonable to postulate that the net rate of acquiring fertilizing potential will reflect the interaction between braking, or inhibitory, and accelerating, or stimulatory, effectors. This article focuses on two endogenous molecules, one that exerts inhibitory effects and one that exerts initially stimulatory and then inhibitory effects. Both have been demonstrated to interact with the sperm surface to modulate sperm fertilizing ability in biologically relevant ways. Defects in either or both could affect fertility in vivo, and in some instances it may be possible to develop new therapeutic strategies to overcome such problems.
Decapacitation factors
It has been known since 1951 that mammalian spermatozoa just released from the male reproductive tract are incapable of fertilizing oocytes immediately, but must spend several hours (usually in the female reproductive tract) before they acquire fertilizing potential. These cells are said to have undergone 'capacitation', i.e. achieved the capacity to fertilize an oocyte. The amount of time required is 39 species-specific and the process is reversible (Yanagimachi, 1994; de Lamirande et al, 1997) . The changes that comprise capacitation are complex and involve alterations both to the sperm surface and to the molecular pathways that operate within spermatozoa. Changes to the sperm surface include the loss, unmasking or rearrangement of molecules (Oliphant et al, 1985; de Lamirande et al, 1997) . Those that are lost are frequently referred to as decapacitation factors (DF) and they can be of either epididymal or seminal plasma origin: their addition to capacitated sperm suspensions will rapidly and significantly inhibit fertilization, i.e. reverse capacitation (Bedford and Chang, 1962; Fraser, 1984) .
For some time, we have been studying a mouse sperm DF of epididymal origin that is lost or inactivated as capacitation proceeds in vitro. Since the timing of capacitation in vitro is similar for mouse spermatozoa obtained from both the caudal epididymis and from the uterine horns of females shortly after natural mating (Fraser, 1983) , this DF would appear to be the major inhibitory molecule involved in controlling the acquisition of fertilizing ability both in vivo and in vitro. Gentle centrifugation of uncapacitated mouse spermatozoa will remove DF, and suspensions that are then resuspended in fresh medium are significantly more fertile when tested in vitro than their uncentrifuged counterparts. However, if capacitated suspensions are exposed to either crude DF (cell-free supernatant obtained by centrifuging uncapacitated cells) or partially purified DF (Fraser et al, 1990) , then fertilizing ability is significantly lower than that obtained with untreated controls. Chlortetracycline (CTC) fluorescence has revealed that suspensions treated this way exhibit a significant inhibition of the spontaneous acrosome reaction coupled with a reversion from the capacitated, acrosomeintact state to the uncapacitated, acrosome-intact state (Fraser et al, 1990) .
CTC analysis has proved to be immensely useful in evaluating the effects of specific treatments on capacitation and therefore on functional ability. The commonly used cytological techniques only identify acrosome-intact and acrosome-reacted cells, yet the category of greatest interest is that of capacitated, acrosome-intact cells because these are the potentially fertilizing cells. There is a direct correlation between the CTC fluorescence patterns and the presence or absence of DF. The removal of DF by centrifugation causes a significant shift from the uncapacitated to the capacitated but still acrosome-intact pattern, while the addition of DF to capacitated suspensions causes the reverse shift from the capacitated to the uncapacitated, acrosome-intact pattern. The fact that this latter backward shift occurs when partially purified mouse sperm DF is added to capacitated suspensions of both epididymal mouse spermatozoa (Fraser et al, 1990) and ejaculated human spermatozoa (DasGupta et al, 1994) would suggest that the mechanism of action of DF is not unique to mouse gametes but may represent mechanisms that operate in several or even all species of mammalian spermatozoa.
If that is the case, then what is the mechanism involved? Current evidence indicates that the DF, when attached to the sperm surface, activates an intracellularly located Ca 2+ -ATPase (Adeoya-Osiguwa and Fraser, 1996) and so helps to maintain a low concentration of intracellular Ca 2+ ([Ca 2+ ]j). As the DF is lost or inactivated by as yet unidentified mechanisms during capacitation, there is a modest rise in [Ca 2+ ]j (Florman, 1994; Suarez and Dai, 1995) . In addition to both indirect and direct evidence supporting this mechanism of action (see Fraser, 1995; Adeoya-Osiguwa and Fraser, 1996) , an intracellularly located Ca 2+ -ATPase was identified in the postacrosomal region, the same region where CTC fluorescence changes, depending on the removal or addition of DF molecules to spermatozoa. Furthermore, the addition of exogenous DF to capacitated cells significantly inhibited the initial ability of these cells to accumulate 45 Ca 2+ ; with time, the DF was lost and cells were able to accumulate labelled Ca 2+ (Adeoya-Osiguwa and Fraser, 1996) . A rise in [Ca 2+ ]j would have a number of effects within capacitating cells, e.g. stimulation of adenylyl cyclase (AC) and consequent production of cyclic AMP (cAMP) (Fraser, 1995) .
Biochemical characterization of a partially purified DF preparation revealed that it is an anionic protein of -40 kDa. It is stable to heating at 100°C and to proteolysis at pH 8.0, suggesting that sugar residues may be involved in its biological activity (Fraser et al, 1990) . The most recent evidence indicates that (i) the DF, rather than binding directly to the sperm plasma membrane, binds to a receptor that is inserted into the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor and (ii) fucose residues on the DF are involved in binding to the receptor. DF was removed precociously from uncapacitated cells by incubating them in the presence of phosphatidylinositol-specific phospholipase C (PIC), but DF could not reassociate with PIC-treated cells and reverse the capacitation process because the receptor had been removed. A brief incubation of capacitated cells in the presence of fucose at 0.1-10 mmol/1 before the addition of exogenous DF also prevented the reversal of capacitation. Conversely, the addition of fucose to uncapacitated suspensions resulted in a displacement of DF, leading to significantly accelerated capacitation and increased fertilizing ability in vitro (Fraser, 1998) . Finally, binding of both fucosylated fluoroscein isothiocyanate (FITC)-labelled bovine serum albumin (BSA) and FITC-labelled UEA I (lectin from Ulex europaeus with specificity for oc-L-fucose) was localized to the postacrosomal region; binding was significantly inhibited if cells were exposed to crude DF prior to the labelled BSA or lectin (Fraser, 1998) . Although the normal mechanism that promotes loss of DF is unknown at present, it is clear that defects would result in significantly reduced fertility.
Fertilization-promoting peptide
DF molecules work by inhibiting a specific mechanism, so loss of DF leads to a stimulation of capacitation. There is evidence for the existence of another category of molecules, stimulatory ones, that gain access to spermatozoa at the time of ejaculation. Although there is a tendency to think of seminal plasma as containing molecules that act primarily to inhibit sperm function, this is incorrect. Fertilization-promoting peptide (FPP; pGlu-Glu-ProNH 2 ), structurally related to thyrotrophin-releasing hormone (TRH; pGlu-His-ProNH 2 ), is produced by the prostate gland and secreted into the seminal plasma where it is found at a mean concentration of -50 nmol/1 (human; Cockle et al, 1994) . The peptide has been given its name because experimental evidence indicates that it can stimulate capacitation and hence fertilizing ability in mammalian spermatozoa (Green etal., 1994) .
FPP accelerates capacitation and stimulates fertilizing ability in both uncapacitated mouse spermatozoa (Green et al, 1994) and human spermatozoa (Green et al, 1996a) . The use of CTC in the initial evaluation of peptide-treated cells was crucial to the success of these studies, since the peptide significantly stimulated capacitation but had no significant effect on the spontaneous acrosome reaction. CTC analysis suggested that peptide-treated cells would be more fertile than untreated controls and in-vitro fertilization (IVF) studies confirmed this.
Subsequent studies on mouse spermatozoa revealed that FPP also has a significant effect on capacitated cells: it inhibits spontaneous acrosome loss in capacitated cells, although the cells retain their ability to undergo the acrosome reaction in response to progesterone (Green et al., 1996b) . This biphasic response was reminiscent of an earlier study that revealed a biphasic effect of adenosine on AC activity in mouse spermatozoa (Stein et al., 1986) . When adenosine was evaluated using the FPP protocols, similar responses were observed: adenosine stimulated capacitation in uncapacitated cells and then inhibited spontaneous acrosome loss in capacitated suspensions (Green et al., 1996b) . Additional experiments revealed that FPP + adenosine elicited a greater response than either used individually, whether at low, non-stimulatory or high, maximally stimulatory concentrations. This led to the proposal that FPP and adenosine act via the same signal transduction pathway, but interact with different, specific receptors. Since adenosine has been shown to modulate the AC/cAMP pathway in mouse spermatozoa via specific adenosine receptors on the cell surface (Fraser and Duncan, 1993) , it has been proposed that FPP also works via that pathway. Current evidence indicates that FPP can stimulate cAMP production in mouse sperm membrane preparations, permeabilized cells and live, intact cells (AdeoyaOsiguwa et al, 1998) .
In addition to FPP, a number of related peptides have been identified in the prostate gland and/or seminal plasma, especially of men with prostatic dysfunction . Some of these related peptides have been evaluated in vitro and all have proved to be less effective than FPP (Fraser et al, 1997a) . Of particular interest was Gln-FPP (pGlu-Gln-ProNH 2 ), a peptide identified in human seminal plasma (Khan et al, 1992) . Gln-FPP had no biological activity when used alone, but when used in combination with FPP it inhibited responses to FPP in a concentration-dependent manner (Fraser et al, 1997a) . These results suggest that Gln-FPP can compete with FPP for FPP-specific binding sites. Consistent with this, Gln-FPP significantly inhibited the specific binding of [ 3 H]FPP to mouse sperm membranes, whereas adenosine did not (AdeoyaOsiguwa et al, 1998) . This would be predicted if FPP and adenosine act via different receptors.
These results suggested the presence of an FPP-specific receptor. Rather serendipitously, a candidate molecule has now been identified: it is TCP11, the protein coded for by the mouse t-complex gene Tcpll, which has a human homologue (Ragoussis et al, 1992) . Genes in the t-complex, found on chromosome 17, are known to affect male but not female fertility (Bennett, 1975; Silver, 1985) . Male mice heterozygous for the t-complex produce t-chromosome and wild-type chromosome-carrying spermatozoa in equal proportions, but in many cases >90% of their offspring will have been fertilized by t-bearing cells. Thus the t-bearing spermatozoa would appear to have a functional advantage, at least in vivo. The gene Tcpll is expressed only in the germ cells in the testis (Mazarakis et al, 1991) ; it is transcribed late in meiosis and then translated during spermiogenesis (Hosseini et al, 1994) . Using purified anti-TCPll immunoglobulin G (IgG) antibodies, the protein has been localized on the surface of epididymal mouse spermatozoa. Specifically, it is found on the acrosomal cap region of acrosome-intact but not acrosome-reacted cells and on the flagella of essentially all cells, being most abundant on the principal piece and with very variable density on the midpiece (Fraser et al, 1997b) .
To investigate a possible role for TCP11 relating to sperm function, Fab fragments of anti-TCPll IgG antibodies were used. Fab fragments significantly stimulated capacitation in uncapacitated epididymal mouse sperm suspensions and, with extended incubation, significantly inhibited spontaneous acrosome loss in capacitated suspensions. Subsequent IVF experiments demonstrated that Fabtreated suspensions became fertile more quickly than controls and then maintained high fertilizing ability, despite the presence of the antibodies (Fraser et al, 1997b) . Since these responses were the same as those obtained with FPP, it was postulated that TCP 11 may be the receptor for FPP. Consistent with this, Gln-FPP was able to inhibit competitively responses to the Fab fragments, but adenosine was not (Fraser et al, 1997b (Adeoya-Osiguwa et al, 1998) .
The proposed interactions between FPP and TCP11, resulting in modulation of AC/cAMP and.consequent biologically important changes in sperm function, could play an important role in vivo. By stimulating capacitation and then inhibiting spontaneous acrosome loss, FPP and adenosine would enable spermatozoa to retain fertilizing potential until they encountered an oocyte, an important factor since relatively few cells reach the site of fertilization.
Future prospects
Current evidence suggests that at least some instances of 'male factor' infertility are due to sperm dysfunction. The two mechanisms addressed in this article have been demonstrated to play fundamental roles in the 'switching on' of fertilizing potential in vitro. Since both effectors, DF and FPP, are endogenous molecules, it is plausible that they could play similar roles in vivo to those shown in vitro.
Defects in either system could result in capacitation failure and therefore fertilization failure. In some individuals, this might reflect an inability to lose or inactivate DF molecules, resulting in continuous activation of Ca 2+ -ATPase and maintenance of a low [Ca 2+ ]j. It might be possible to develop methods to promote removal of DF, e.g. use of exogenous fucose which was able to displace endogenous mouse sperm DF and significantly stimulate fertilizing ability. In other cases, the failure to achieve conception might reflect: (i) low concentrations of FPP; (ii) the presence of FPP-related peptides which either are less biologically active than FPP or are able competitively to inhibit responses to FPP; (iii) an alteration in TCP11, the putative receptor, which could either reduce or abolish the response to FPP. Deficiencies of FPP could be overcome by, for example, adding exogenous FPP to washed spermatozoa for use in either intrauterine insemination or IVF; alternatively, FPP could be incorporated into a cream or jelly designed to be inserted into the vagina. Such treatment could have two effects: (i) increasing the chance of fertilization if spermatozoa encountered an oocyte and (ii) ensuring that penetration would occur relatively quickly since, in stimulating capacitation, FPP stimulates hyperactivation which will promote penetration of the zona pellucida. If the problem proved to be a defective TCP 11 molecule, then it should be possible to stimulate the cells at a step in the sequence that normally occurs after AC activation.
By learning more about the fundamental mechanisms that control normal sperm function, it should be possible to develop more precise tests to diagnose defects and then to develop new therapeutic treatments designed to overcome the specific defect.
